trial
as of 2026-07-01Switching to Iloperidone From Other Antipsychotics in Schizophrenia
NCTId NCT01207414
at a glance
Phase 4 · Completed
Enrollment 501 (actual)
Sponsored by Novartis Pharmaceuticals
Primary completion 2012-01
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Completed
Enrollment
501 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2010-08
Primary completion
2012-01
Eligibility
ALL · 18 Years · 64 Years
Interventions & indications
Drugs
Indications
Sponsors
Novartis PharmaceuticalsLead Sponsor
Investigators
1
Marla Hochfeld, MD, MDStudy Director
Sites
59 total
Birmingham, United StatesCerritos, United StatesCosta Mesa, United StatesGarden Grove, United StatesLong Beach, United StatesNational City, United StatesOakland, United StatesOceanside, United StatesOrange, United StatesSan Diego, United StatesSan Diego, United StatesSan Diego, United States
Facts & assertions
4 sourced
Enrollment
501
Phase
PHASE4
Primary Completion Date
2012-01
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication
indication
indication
investigator
person